AstraZeneca Pharma India Limited has received a substantial demand notice amounting to ₹1,48,65,83,590 from the National Pharmaceutical Pricing Authority (NPPA). The notice alleges overcharging under the Drugs (Prices Control) Order, 2013, specifically for Symbicort Turbuhaler 160/4.5 during the period of May 2016 to November 2025. The company is currently evaluating the notice and considering appropriate legal actions.
NPPA Issues Demand Notice to AstraZeneca India
AstraZeneca Pharma India Limited has disclosed the receipt of a significant demand notice from the National Pharmaceutical Pricing Authority (NPPA). The notice, dated July 29, 2026, pertains to allegations of overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013).
Details of the Demand Notice
The demand notice, valued at Rs. 1,48,65,83,590, inclusive of interest calculated up to August 20, 2026, follows a prior show-cause notice issued on September 11, 2025. The alleged overcharging relates to the product Symbicort Turbuhaler 160/4.5 (Inhaler) for the period spanning from May 2016 to November 2025. The NPPA has mandated payment of the demanded amount within 30 days of receiving the notice.
Company’s Response and Next Steps
AstraZeneca India stated that it is currently in the process of evaluating the demand notice thoroughly. The company is also exploring and considering appropriate legal actions in response to the NPPA’s directive. Further updates are expected as the evaluation progresses.
Source: BSE
